Digital Pathology Tailored for Assessment of Liver Biopsies DOI Creative Commons
Alina-Iuliana Onoiu, David Parada, Jorge Joven

и другие.

Biomedicines, Год журнала: 2025, Номер 13(4), С. 846 - 846

Опубликована: Апрель 1, 2025

Improved image quality, better scanners, innovative software technologies, enhanced computational power, superior network connectivity, and the ease of virtual reproduction distribution are driving potential use digital pathology for diagnosis education. Although relatively common in clinical oncology, its application liver is under development. Digital improving subjective histologic scoring systems could be essential managing obesity-associated steatotic disease. The increasing analyzing specimens particularly intriguing as it may offer a more detailed view biology eliminate incomplete measurement treatment responses trials. objective automated quantification histological results help establish standardized diagnosis, treatment, assessment protocols, providing foundation personalized patient care. Our experience with artificial intelligence (AI)-based enhances reproducibility accuracy, enabling continuous detecting subtle changes that indicate disease progression or regression. Ongoing validation highlights need collaboration between pathologists AI developers. Concurrently, analysis can address issues related to historical failure trials stemming from challenges assessment. We discuss how these novel tools incorporated into research complement post-diagnosis scenarios where necessary, thus clarifying evolving role field.

Язык: Английский

Precision in Diagnosis of Liver Fibrosis in MASLD: Machine Learning‐Based Scores May Be More Accurate Than Conventional NITs DOI Open Access
Reham Soliman,

A Helmy,

Gamal Shiha

и другие.

Liver International, Год журнала: 2025, Номер 45(4)

Опубликована: Март 3, 2025

Язык: Английский

Процитировано

1

Response to: Precision in Diagnosis of Liver Fibrosis in MASLD: Machine Learning Based Scores May Be More Accurate Than Conventional NITs DOI Open Access
Yasaman Vali, Quentin M. Anstee, Patrick M. Bossuyt

и другие.

Liver International, Год журнала: 2025, Номер 45(5)

Опубликована: Март 29, 2025

We thank Soliman et al. for their thoughtful comments on our recent publication [1]. appreciate insights and the opportunity to further discuss role of machine learning (ML)-based non-invasive tests (NITs) in diagnosis metabolic dysfunction-associated steatotic liver disease (MASLD). As we previously demonstrated LITMUS study, ML models incorporating clinical biomarker data can enhance detection nonalcoholic steatohepatitis (NASH) at-risk NASH, highlighting potential ML-based approaches diagnostics [2]. Expanding fibrosis assessment, highlight scores, particularly FIB-6 index, improving accuracy assessment MASLD [3]. Their multicenter study that score, which integrates multiple routine laboratory parameters, could offer advantages sensitivity negative predictive value (NPV) compared conventional NITs like FIB-4 or APRI [4]. also utility resource-limited settings, where advanced imaging techniques transient elastography may not be readily available. However, generalisability these scores across diverse populations settings remains fully validated. While has been evaluated cohorts patients with chronic hepatitis C, B, MASLD, studies are needed assess its performance primary care comorbidities beyond those studied. In addition, while such as hold promise refining diagnostic accuracy, implementation requires careful consideration. Our emphasised importance tailoring NIT thresholds individual patient characteristics, age, body mass index (BMI), diabetes status, optimise accuracy. This approach aligns principles personalised medicine enhanced by models. acknowledged findings primarily reflect secondary tertiary need research populations. Moreover, leveraged rigorous histological assessments from centres, variability biopsy interpretation a recognised limitation. The upcoming results cohort, using centralised AI-based pathology, will provide into standardised evaluation. conclusion, represent promising advancement diagnosis, integration practice should guided validation consideration patient-specific factors. look forward future explore other diseases. authors declare no conflicts interest.

Язык: Английский

Процитировано

0

Digital Pathology Tailored for Assessment of Liver Biopsies DOI Creative Commons
Alina-Iuliana Onoiu, David Parada, Jorge Joven

и другие.

Biomedicines, Год журнала: 2025, Номер 13(4), С. 846 - 846

Опубликована: Апрель 1, 2025

Improved image quality, better scanners, innovative software technologies, enhanced computational power, superior network connectivity, and the ease of virtual reproduction distribution are driving potential use digital pathology for diagnosis education. Although relatively common in clinical oncology, its application liver is under development. Digital improving subjective histologic scoring systems could be essential managing obesity-associated steatotic disease. The increasing analyzing specimens particularly intriguing as it may offer a more detailed view biology eliminate incomplete measurement treatment responses trials. objective automated quantification histological results help establish standardized diagnosis, treatment, assessment protocols, providing foundation personalized patient care. Our experience with artificial intelligence (AI)-based enhances reproducibility accuracy, enabling continuous detecting subtle changes that indicate disease progression or regression. Ongoing validation highlights need collaboration between pathologists AI developers. Concurrently, analysis can address issues related to historical failure trials stemming from challenges assessment. We discuss how these novel tools incorporated into research complement post-diagnosis scenarios where necessary, thus clarifying evolving role field.

Язык: Английский

Процитировано

0